Vitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.
Vitaly Margulis, MD
Advertisement
Vitaly Margulis, MD, is a professor of urology at UT Southwestern Medical Center.
Articles by Vitaly Margulis, MD
Vitaly Margulis, MD, reflects on the secondary end points findings and safety data from the Apa-RP study in high-risk localized prostate cancer.
Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer.
Vitaly Margulis, MD, discusses the Apa-RP study of adjuvant treatment consisting of apalutamide and androgen deprivation therapy in patients with high-risk localized prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
